Physician profile
James E Dowd
NPI 1750482162
$999.11
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.00 · 2020: $79.26 · 2021: $29.75 · 2022: $419 · 2023: $294 · 2024: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $346.44 | 2019-2023 | Tremfya |
| Ucb, INC. | $173.83 | 2022-2024 | Cimzia |
| Lilly USA, LLC | $117.61 | 2022-2024 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $99.44 | 2022-2024 | Saphnelo |
| Amgen INC. | $37.28 | 2022 | |
| Aurinia Pharma U.S., INC. | $37.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.55 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.29 | 2023-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $31.72 | 2024 | Orencia |
| Organon LLC | $31.10 | 2022 | |
| Pfizer INC. | $29.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.25 | 2019 | |
| Abbvie INC. | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dowd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.